Bio-Rad Laboratories (BIO-B) Net Cash Flow (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Net Cash Flow data on file, last reported at -$29.1 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$29.1 million, down 182.91% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.9 million (down 105.79% YoY), and the FY2025 annual result was $59.3 million, down 22.18% from the prior year.
• Net Cash Flow fell to -$29.1 million in Q1 2026 per BIO-B's latest filing, from $134.0 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $324.7 million in Q1 2022 and troughed at -$212.5 million in Q2 2022.
• A 5-year average of $2.1 million and a median of $11.9 million in 2024 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 1710.06% in 2022 and fell as far as 471.66% in 2022.
• A 5-year view of Net Cash Flow shows it stood at -$65.5 million in 2022, then rose by 27.71% to -$47.4 million in 2023, then surged by 242.47% to $67.5 million in 2024, then jumped by 98.52% to $134.0 million in 2025, then slumped by 121.72% to -$29.1 million in 2026.
• Business Quant data shows BIO-B's Net Cash Flow at -$29.1 million in Q1 2026, $134.0 million in Q4 2025, and $25.4 million in Q3 2025.